James Galvin
James Galvin
Professor of Neurology, University of Miami Miller School of Medicine
Verified email at miami.edu
Title
Cited by
Cited by
Year
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium
IG McKeith, DW Dickson, J Lowe, M Emre, JT O'brien, H Feldman, ...
Neurology 65 (12), 1863-1872, 2005
50982005
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
IG McKeith, BF Boeve, DW Dickson, G Halliday, JP Taylor, D Weintraub, ...
Neurology 89 (1), 88-100, 2017
17342017
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ...
Jama 304 (17), 1903-1911, 2010
7422010
The AD8: a brief informant interview to detect dementia
JE Galvin, CM Roe, KK Powlishta, MA Coats, SJ Muich, E Grant, JP Miller, ...
Neurology 65 (4), 559-564, 2005
7252005
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
HI Hurtig, JQ Trojanowski, J Galvin, D Ewbank, ML Schmidt, VMY Lee, ...
Neurology 54 (10), 1916-1921, 2000
6562000
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein
P Tu, JE Galvin, M Baba, B Giasson, T Tomita, S Leight, S Nakajo, ...
Annals of neurology 44 (3), 415-422, 1998
6451998
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers
CF Lippa, JE Duda, M Grossman, HI Hurtig, D Aarsland, BF Boeve, ...
Neurology 68 (11), 812-819, 2007
5962007
Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
Y Iturria-Medina, RC Sotero, PJ Toussaint, JM Mateos-Pérez, AC Evans
Nature communications 7 (1), 1-14, 2016
5882016
Synucleinopathies: clinical and pathological implications
JE Galvin, VMY Lee, JQ Trojanowski
Archives of neurology 58 (2), 186-190, 2001
5212001
Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein
JE Galvin, K Uryu, VMY Lee, JQ Trojanowski
Proceedings of the National Academy of Sciences 96 (23), 13450-13455, 1999
4571999
Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease
ER Siemers, JF Quinn, J Kaye, MR Farlow, A Porsteinsson, P Tariot, ...
Neurology 66 (4), 602-604, 2006
4042006
Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease
AS Fleisher, R Raman, ER Siemers, L Becerra, CM Clark, RA Dean, ...
Archives of neurology 65 (8), 1031-1038, 2008
3912008
Validity and reliability of the AD8 informant interview in dementia
JE Galvin, CM Roe, C Xiong, JC Morris
Neurology 67 (11), 1942-1948, 2006
3342006
Longitudinal study of the transition from healthy aging to Alzheimer disease
DK Johnson, M Storandt, JC Morris, JE Galvin
Archives of neurology 66 (10), 1254-1259, 2009
3082009
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
M Sano, KL Bell, D Galasko, JE Galvin, RG Thomas, CH Van Dyck, ...
Neurology 77 (6), 556-563, 2011
2962011
Distinguishing Alzheimer’s disease from other major forms of dementia
S Karantzoulis, JE Galvin
Expert review of neurotherapeutics 11 (11), 1579-1591, 2011
2842011
Clinical phenotype of Parkinson disease dementia
JE Galvin, J Pollack, JC Morris
Neurology 67 (9), 1605-1611, 2006
2572006
Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
MM Williams, C Xiong, JC Morris, JE Galvin
Neurology 67 (11), 1935-1941, 2006
2412006
Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study
JE Galvin, KK Powlishta, K Wilkins, DW McKeel, C Xiong, E Grant, ...
Archives of neurology 62 (5), 758-765, 2005
2262005
Curcumin inhibits aggregation of α-synuclein
N Pandey, J Strider, WC Nolan, SX Yan, JE Galvin
Acta neuropathologica 115 (4), 479-489, 2008
2232008
The system can't perform the operation now. Try again later.
Articles 1–20